Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Genomics Licenses Biomarkers from Garvan Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clinical Genomics today said that it has licensed rights to certain cancer biomarkers from The Garvan Institute of Medical Research.

The Sydney, Australia-based firm said that it has obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer. Clinical Genomics said that it will evaluate the biomarkers for possible development of diagnostic tests for early detection of colorectal cancer.

"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," Lawrence LaPointe, CEO of Clinical Genomics, said in a statement.

The Garvan Institute, which also is based in Sydney, focuses on genetics research in cancer and metabolic syndromes.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.